Live
FierceBiotechTenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater ChinaFierceBiotechFDA greenlights backup anti-choking suction deviceFierceBiotechXenon phase 3 epilepsy readout 'blows away' expectations, stock soarsFierceBiotechBMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3AgilentAgilent to buy Biocare Medical for $950M - MedTech DiveBioPharma DiveIpsen to withdraw cancer drug acquired in buyout due to safety concernsEndpoints NewsUniversal Health Services buys Talkspace for $835MEndpoints NewsAbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in ChinaBioPharma DiveNovo, Hims reach deal to sell GLP-1 drugs togetherLonza NewsLonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO - the-scientist.comEndpoints NewsXenon gets Phase 3 win with epilepsy drug, setting up FDA approval filingBioWorldBiggest gainers and losers for March 2-6, 2026
Agilent Mar 8, 2026

Agilent Technologies (A) Is Down 5.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - simplywall.st

Agilent Technologies (A) Is Down 5.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - simplywall.st

Original
Body unavailable. Use the original source.

Directory

59 All